In a filing, Syndax Pharmaceuticals Inc revealed its Chief Executive Officer Metzger Michael A unloaded Company’s shares for reported $0.12 million on Mar 04 ’25. In the deal valued at $15.05 per share,7,814 shares were sold. As a result of this transaction, Metzger Michael A now holds 300,121 shares worth roughly $3.76 million.
Then, MICHAEL METZGER bought 13,888 shares, generating $214,986 in total proceeds.
Before that, Goldan Keith A. sold 3,777 shares. Syndax Pharmaceuticals Inc shares valued at $58,559 were divested by the Chief Financial Officer at a price of $15.50 per share. As a result of the transaction, Goldan Keith A. now holds 90,746 shares, worth roughly $1.14 million.
UBS initiated its Syndax Pharmaceuticals Inc [SNDX] rating to a Buy in a research note published on October 24, 2024; the price target was $37. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Scotiabank also remained covering SNDX and has decreased its forecast on January 31, 2024 with a “Sector perform” recommendation from previously “Sector outperform” rating. Mizuho started covering the stock on December 22, 2023. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Monday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock fall -6.63% to $12.53. Over the last five days, the stock has lost -19.06%. Syndax Pharmaceuticals Inc shares have fallen nearly -5.22% since the year began. Nevertheless, the stocks have fallen -47.24% over the past one year. While a 52-week high of $25.16 was reached on 02/21/25, a 52-week low of $12.06 was recorded on 01/14/25. SMA at 50 days reached $14.25, while 200 days put it at $18.00.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 12.15, which if violated will result in even more drops to 11.76. On the upside, there is a resistance level at 13.16. A further resistance level may holdings at 13.78. The Relative Strength Index (RSI) on the 14-day chart is 31.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.93%. Stochastics %K at 7.28% indicates the stock is a buying.
The most recent change occurred on October 25, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
